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Abstract 
 
The availability of new psychoactive substances on the recreational drug 
market continues to create challenges for scientists in the forensic, clinical 
and toxicology fields. Phenmetrazine (3-methyl-2-phenylmorpholine) and an 
array of its analogs form a class of psychostimulants that are well 
documented in the patent and scientific literature. The present study reports 
on two phenmetrazine analogs that have been encountered on the NPS drug 
market following the introduction of 3-fluorophenmetrazine (3-FPM), namely 
4-methylphenmetrazine (4-MPM) and 3-methylphenmetrazine (3-MPM). This 
study describes the syntheses, analytical characterization and 
pharmacological evaluation of the positional isomers of MPM. Analytical 
characterizations employed various chromatographic, spectroscopic and 
mass spectrometric platforms. Pharmacological studies were conducted in 
order to assess whether MPM isomers might display stimulant-like effects 
similar to the parent compound phenmetrazine. The isomers were tested for 
their ability to inhibit uptake or stimulate release of tritiated substrates at 
dopamine, norepinephrine and serotonin transporters using in vitro transporter 
assays in rat brain synaptosomes. The analytical characterization of three 
vendor samples revealed the presence of 4-MPM in two of the samples and 
3-MPM in the third sample, which agreed with the product label. The 
pharmacological findings suggest that 2-MPM and 3-MPM will exhibit 
stimulant properties similar to the parent compound phenmetrazine, whereas 
4-MPM may display entactogen properties more similar to MDMA. The 
combination of test purchases, analytical characterization, targeted organic 
synthesis and pharmacological evaluation of NPS and their isomers is an 
effective approach for the provision of data on these substances as they 
emerge in the marketplace. 
 
 
Keywords: New psychoactive substances; psychostimulants; phenmetrazine; 
fluorophenmetrazine; monoamine transporters 
  
Accepted for publication in Drug Testing and Analysis 13.04.2018 
	 3 
1. Introduction 
 
Phenmetrazine (3-methyl-2-phenylmorpholine; Preludin®) (Figure 1A) is a 
synthetic amphetamine derivative that consists of a phenylisopropylamine 
skeleton with the terminal amine incorporated into a morpholine ring.1 
Phenmetrazine hydrochloride, the active ingredient of Preludin, was 
introduced as an anorectic medication in the 1950s along with its N-
methylated analog phendimetrazine.2 Rothman et al. showed that 
phenmetrazine is a potent substrate-type releaser at dopamine transporters 
(DAT) and norepinephrine transporters (NET), with less potent effects at 
serotonin transporters (SERT).3 Phendimetrazine (Bontril®) (Figure 1A) is 
classified as a pro-drug that exerts its pharmacological effects via N-
demethylation to form phenmetrazine.1,4,5 Phenmetrazine is listed as a 
Schedule II drug under the United Nations Convention on Psychotropic 
Substances 1971,2,6 whereas phendimetrazine is listed in Schedule IV of the 
same Convention.6 Phenmetrazine was removed from clinical use due to 
concerns about abuse and dependence.  Nevertheless, following its removal 
from the clinical market, phenmetrazine remained a popular stimulant 
(‘prellies’) on the recreational drug market. 
 
Phenmetrazine and an array of its analogs form a class of compounds that 
are well documented in the patent and scientific literature.1 Emerging 
evidence suggests that phendimetrazine may be an efficacious candidate 
treatment for cocaine dependence.7-9 However, recent reports indicate that 
scientific information about phenmetrazine and its analogs is being utilized by 
manufacturers of new psychoactive substances (NPS), which are offered for 
uncontrolled sale.10,11 The manipulation of the phenmetrazine structure by 
substitution on the phenyl or morpholine rings creates a variety of suitable 
candidates for the NPS market. 2-(3-Fluorophenyl)-3-methylmorpholine (3-
fluorophenmetrazine; 3-FPM; PAL-593), 2-(4-fluorophenyl)-3-
methylmorpholine (4-fluorophenmetrazine; 4-FPM; PAL-748), 2-(3-
methylphenyl)-3-methylmorpholone (3-methylphenmetrazine; 3-MPM; PAL-
773) and 2-(4-methylphenyl)-3-methylmorpholine (4-methylphenmetrazine; 4-
MPM; PAL 747) are phenmetrazine analogs that first appeared in a patent 
application by Blough et al. in 2011.1 All of the aforementioned compounds 
were synthesized and pharmacological evaluations revealed that the 
compounds were substrate-type monoamine releasers with high selectivity 
towards DAT and NET. Furthermore, addition of a methyl group to the phenyl 
ring generally increased potency at SERT.1 
 
In 2014, 3-FPM was first notified by the European Monitoring Centre for Drugs 
and Drug Addiction (EMCDDA) Early Warning System (EWS).12 A recent 
study on fluorophenmetrazine provided the analytical profile of all three 
positional isomers (2-, 3- and 4-FPM) and identified 3-FPM in a number of 
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samples obtained from Internet vendors.11 Pharmacological studies on the 
three fluorophenmetrazine isomers revealed that 3-FPM and its positional 
isomers are substrate-type releasing agents at monoamine transporters with 
marked potency at DAT and NET, which suggests that these compounds 
might display abuse and dependence liability.13 A published case report found 
an association between the intravenous use of 3-FPM and acute kidney injury 
and critical limb ischaemia.14 3-FPM has also been detected in biological 
samples obtained from a multiple-drug fatality.15 In addition, a 2016 study 
identified the main in vivo phase I and II metabolites of 3-FPM in human and 
rat urine, and reported on the microbial biotransformation products of 3-
FPM.10 A recent study by Bäckberg et al. described the non-fatal intoxications 
of several patients involving 3-FPM.16 3-FPM is still available for purchase on 
vendor websites. 
 
The present study reports on two phenmetrazine analogs that have been 
encountered on the NPS drug market following the introduction of 3-FPM, 
namely 4-methylphenmetrazine (4-MPM) and 3-methylphenmetrazine (3-
MPM) (Figure 1A). 4-MPM was notified by the EMCDDA EWS in October 
2015.17 Subsequently, 3-MPM was notified by the EMCDDA EWS in July 
2016.18 However, information about the 2-methylphenmetrazine (2-MPM) 
positional isomer (Figure 1A) could not be identified, which made it necessary 
to investigate the organic synthesis of the ortho-, meta- and para- substituted 
isomers to facilitate their analytical differentiation. Various chromatographic, 
spectroscopic and mass spectrometric platforms were employed followed by 
structural investigations using X-ray crystal structure analysis.  In order to 
assess whether these methylphenmetrazine isomers might display stimulant-
like effects similar to the parent compound, the isomers were tested for their 
ability to inhibit uptake and induce release of tritiated substrates at DAT, NET 
and SERT using in vitro transporter assays in rat brain synaptosomes. In 
these experiments, the parent compound phenmetrazine was included as a 
standard reference compound with known pharmacology. 
 
2. Experimental 
 
2.1 Reagents and standards 
 
All reagents and dry solvents used in the syntheses were obtained from 
Sigma Aldrich Ltd (Arklow, Co. Wicklow, Ireland). 2- and 3-
Methylpropiophenone were obtained from Fluorochem (Derbyshire, United 
Kingdom). 4-Methylpropiophenone was obtained from Sigma Aldrich Ltd 
(Arklow, Co. Wicklow, Ireland). Preparative silica gel thin layer 
chromatography plates (UV254, GF 20 x 20 cm, 2000 microns) were obtained 
from Analtech (Newark, NJ, USA). LC-MS grade solvents were obtained from 
Fisher Scientific (Dublin, Ireland). Three samples, two advertised as 4-
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methylphenmetrazine and one as 3-methylphenmetrazine, were obtained 
from two different Internet vendors. 
 
 
2.2 Synthesis 
 
2.2.1 3-Methyl-2-(4-methylphenyl)morpholine (4-methylphenmetrazine, 4-
MPM, PAL-747) 
 
A solution of bromine (27 mmol, 4.37 g, 1.4 mL) in dichloromethane (26 mL) 
was added slowly to a solution of 4-methylpropiophenone (27 mmol, 4.0 g) in 
dichloromethane (26 mL). The mixture was stirred for 1 h, dried (anhydrous 
magnesium sulphate (MgSO4)) and the solvent removed to afford 2-bromo-1-
(4-methylphenyl)propan-1-one as a colorless oil (20 mmol, 4.5 g). A portion of 
the oil, 0.295 g (1.3 mmol), ethanolamine (1.38 mmol, 0.084 g) and N,N-
diisopropylethylamine (5.12 mmol, 0.672 g, 905 µL) were added to 8 x 2 mL 
Supelco micro reaction vessels and heated at 120–125 oC for 30 min and 
then allowed to cool to room temperature. The mixture from each reaction 
vessel was pooled and partitioned between aqueous hydrochloric acid (2 M) 
(25 mL) and diethyl ether (25 mL). The aqueous layer was washed repeatedly 
with diethyl ether and each aqueous fraction was pooled and made basic with 
aqueous sodium hydroxide (10 M). The basic aqueous fraction was then 
extracted with dichloromethane, the organic extract collected, dried (MgSO4), 
filtered and the volatiles removed under vacuum to afford the intermediates 2-
((2-hydroxyethyl)amino)-1-(4-methylphenyl-)propan-1-one and 3-methyl-2-(4-
methylphenyl)morpholin-2-ol as a ruby oil (5.8 mmol, 1.2 g). This oil was 
dissolved in methanol (12.5 mL) and sodium borohydride (13 mmol, 0.5 g) 
was slowly added. The mixture was stirred at room temp for 2 h and 
partitioned between water and dichloromethane. The organic fraction was 
collected, dried (MgSO4), filtered and the volatiles removed under vacuum to 
afford 2-((2-hydroxyethyl)amino)-1-(4-methylphenyl)propan-1-ol  as a ruby oil 
(6.4 mmol, 1.3 g). This oil was dissolved in dichloromethane and 10 mL 
concentrated sulfuric acid was added and the mixture stirred overnight. The 
reaction was quenched with 250 mL water and made alkaline (10 M NaOH) 
and extracted into dichloromethane. The organic fraction was collected, dried 
(MgSO4), filtered and the volatiles removed under vacuum to give crude 4-
methylphenmetrazine as a ruby oil (0.72 mmol, 0.137 g, 3%). Purification was 
conducted using preparative thin layer chromatography (TLC) using 
methanol/dichloromethane (9:1) as the mobile phase. The purified band was 
isolated from the TLC plate, dissolved in ethanol and centrifuged. Following 
centrifugation, the supernatant was collected, filtered, and the volatiles 
removed yielding the purified 4-methylphenmetrazine (0.2 mmol, 0.035 g, 
1%). 
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2.2.2 Preparation of 4-methylphenmetrazine fumarate salt 
 
To the purified sample (0.2 mmol, 0.035 g), dissolved in 0.5 mL methanol, 
was added fumaric acid (0.2 mmol, 0.021 g) dissolved in 1 mL methanol. The 
solvent was removed and addition of tert.-butyl methyl ether (TBME) afforded 
a white solid powder (0.1 mmol, 0.032 g). m.p. 158–160 oC. 1H NMR (DMSO) 
δ ppm 7.26–7.20 (m; 2 H; H-2’, 6’), 7.20–7.14 (m; 2 H; H-3’, 5’), 6.55 (s; 2 H; 
CH; fumarate CH), 4.12 (d; J = 9.4 Hz; 1 H; H-2), 3.94 (dt; J = 11.8, 2.5 Hz; 1 
H; one H from CH2; H-6), 3.77–3.66 (m; 1 H; CH; one H from CH2; H-6), 3.10–
2.97 (m; 3 H; H-3, 5), 2.30 (s; 3H; CH3 on phenyl ring) and 0.82 (d; J = 6.5 Hz; 
3H; CH3 on morpholine). 
13C NMR (DMSO) δ ppm 167.09 (C=O; fumarate), 
137.42 (C; C4’), 135.84 (C; C-1), 134.60 (CH; fumarate), 128.77 (CH2; C-3’, 
C-5’), 127.40 (CH2; C-2’, C-6’), 82.72 (CH; C-2), 65.14 (CH2; C-6), 54.66 (CH; 
C-3), 44.00 (CH2; C-5), 20.73 (CH3) and 15.89 (CH3). APCI-HRMS Found m/z 
192.138822 (theory [M+H]+: C12H18NO
+ m/z 192.138291, Δ = 2.8 ppm). 
 
2.2.3 3-Methyl-2-(3-methylphenyl)morpholine (3-methylphenmetrazine, 3-
MPM, PAL-773) 
 
The reaction was carried out as described above using 3-
methylpropiophenone instead, yielding crude 3-methylphenmetrazine free 
base as a ruby oil (1.6 mmol, 0.305 g, 6%). Purification was conducted using 
preparative thin layer chromatography (TLC) using methanol/dichloromethane 
(9:1) as the mobile phase. The purified band was isolated from the TLC plate, 
dissolved in ethanol and centrifuged. Following centrifugation, the supernatant 
was collected, filtered, and the volatiles removed yielding the purified 3-
methylphenmetrazine (0.8 mmol, 0.146 g, 3%). The freebase was converted 
to the fumarate salt yielding a white solid (0.5 mmol, 0.146g). m.p. 188–190 
oC. 1H NMR (DMSO) δ ppm 7.27–7.06 (m; 4 H; H-2’, 4’, 5’, 6’), 6.53 (s; 2 H; 
fumarate CH), 4.04 (d; J = 9.2 Hz; 1 H; H-2), 3.91 (ddd; J = 11.5, 3.4, 1.4 Hz; 
2 H; H-6), 3.66 (td; J = 11.4, 3.4 Hz; 1 H; H-3), 3.06–2.86 (m; 2 H; H-5), 2.31 
(s; 3 H; CH3 on phenyl ring) and 0.79 (d; J = 6.5 Hz; 3 H; CH3 on morpholine). 
13C NMR (DMSO) δ ppm 167.92 (C=O; fumarate), 139.70 (C; C-1), 137.73 (C; 
C-3’),135.32 (CH; fumarate), 129.64 (CH; C-4’), 128.48 (CH; C-6’), 128.27 
(CH; C-2’), 125.16 (CH; C-5’), 84.14 (CH; C-2), 66.26 (CH2; C-6), 55.46 (CH; 
C-3), 45.05 (CH2; C-5), 21.45 (CH3) and 16.98 (CH3). APCI-HRMS Found m/z 
192.138879 (theory [M+H]+: C12H18NO
+ m/z 192.138291, Δ = -3.1 ppm). 
 
2.2.4 3-Methyl-2-(2-methylphenyl)morpholine (2-methylphenmetrazine, 2-
MPM) 
 
A solution of bromine (27 mmol, 4.37 g, 1.4 mL) in dichloromethane (26 mL) 
was added slowly to a solution of 2-methylpropiophenone (27 mmol, 4.0 g) in 
dichloromethane (26 mL). The mixture was stirred for 1 h, dried (MgSO4) and 
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the solvent removed to afford 2-bromo-1-(2-methylphenyl)propan-1-one as a 
colorless oil (20 mmol, 4.5 g). A mixture of the 2-bromo-1-(2-
methylphenyl)propan-1-one (4.4 mmol, 1.0 g) ethanolamine (16 mmol, 1.0 g) 
and N-methyl-2-pyrrolidone (0.052 mol, 5.14 g, 5 mL) was stirred at room 
temp. After 3 h, the reaction was quenched with water and made basic (10 M 
NaOH). The mixture was then extracted with ethyl acetate. The organic 
fraction was collected, dried (MgSO4), filtered and the volatiles removed under 
vacuum to afford the intermediates 2-((2-hydroxyethyl)amino)-1-(2-
methylphenyl)propan-1-one and 3-methyl-2-(2-methylphenyl)morpholin-2-ol 
as a colorless oil (8 mmol, 1.70 g). The oil was dissolved in methanol (20 mL) 
and sodium borohydride (16 mmol, 0.6 g) was added. The mixture was stirred 
for 2 h at room temp. The mixture was partitioned between water and 
dichloromethane. The organic fraction was collected, dried (MgSO4), filtered 
and the volatiles removed were removed under vacuum to afford 2-((2-
hydroxyethyl)amino)-1-(2-methylphenyl)propan-1-ol as a colorless oil (5.8 
mmol, 1.201 g). A portion of this intermediate (1.4 mmol, 0.3 g) was dissolved 
in 4 mL dichloromethane and stirring commenced. To this, 8.5 mL of conc. 
sulfuric acid was slowly added followed by stirring for 4–5 h. The addition of 
30 mL water followed and the mixture was made alkaline (10M NaOH) and 
extracted into dichloromethane. The organic fraction was collected, dried, 
filtered and the volatiles were removed under vacuum to give crude 2-
methylphenmetrazine as a ruby oil (0.074 g, 0.4 mmol, 2%).  
 
2.2.5 Preparation of 2-methylphenmetrazine fumarate salt 
 
The sample was converted to the fumarate salt by dissolving 30 mg 2-MPM in 
0.5 mL methanol followed by addition of fumaric acid (0.18 mmol, 0.020 g) 
dissolved in methanol (1 mL). The solvent was removed and the addition of 
TBME afforded a white solid powder (0.07 mmol, 0.020 g). m.p. 182–184 oC. 
1H NMR (DMSO) δ ppm 7.37–3.32 (m; 1 H; H-5’), 7.24–7.11 (m; 3 H; H-3’, 4’, 
6’), 6.52 (s; 2 H; fumarate CH), 4.44 (d; J = 9.4 Hz; 1 H; H-2), 3.91 (dd; J = 
11.4, 3.1 Hz; 1 H; one H from CH2; H-6), 3.78–3.67 (m; 1 H; one H form CH2; 
H-6), 3.10–2.98 (m; 3 H; H-3 and H-5), 2.34 (s; 3 H; CH3 on phenyl ring) and 
0.94-0.80 (m; 3H; CH3 on morpholine). 
13C NMR (DMSO) δ ppm 167.58 
(C=O; fumarate), 137.45 (C; C-2’), 135.55 (C; C-1), 134.89 (CH; fumarate), 
130.04 (CH; C-3’, C-4’), 127.63 (CH; C-6’), 125.90 (CH; C-5’), 79.97 (CH; C-
2), 65.79 (CH2; C-6), 55.12 (CH; C-3), 44.50 (CH2; C-5), 19.26 (CH3) and 
15.84 (CH3). APCI-HRMS Found m/z 192.138787 (theory [M+H]
+: C12H18NO
+ 
m/z 192.138291, Δ = 2.6 ppm). 
 
2.3 Instrumentation 
 
2.3.1 Gas chromatography mass spectrometry 
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Samples were prepared to give a 1 mg/mL solution in methanol and analyzed 
on an Agilent 6890 N GC coupled to a 5975 Mass Selective Detector (Agilent, 
Little Island, Cork, Ireland). A HP-ULTRA 1 column (12 m x 0.2 m x 0.33 µm) 
was used with helium carrier gas at a constant flow of 0.8 mL/min and a spilt 
ratio of 1:1. The injector was set at 250 oC and the transfer line at 280 oC. The 
initial oven temperature was 50 oC, held for 2 min, then ramped at 10 oC/min 
to 100 oC with no hold time. The oven temperature was further ramped at 5 oC 
to 200 oC and then finally ramped at 20 oC to 295 oC with a hold time of 1 min. 
The mass spectra were collected after a 4.0 min solvent delay time. The 
ionization energy was set at 70 eV and the mass range was m/z 40–550. The 
total run time was 32.75 min. 
 
2.3.2 Liquid chromatography mass spectrometry 
 
LC-MS analyses were performed on an Agilent 1100 HPLC system equipped 
with a G13795 degasser, G1312A BinPump, a G1313A ALS and G1316A 
column oven (COLCOM) (Agilent, Little Island, Cork, Ireland). Separation was 
achieved using a Kinetex phenyl-hexyl column (2.6 µm, 100 x 2.10 mm) from 
Phenomenex (Macclesfield, Cheshire, United Kingdom). The analytes were 
eluted under isocratic conditions using a mobile phase of 95% water and 5% 
acetonitrile (both containing 0.1% formic acid). The Agilent LC-MSD settings 
were as follows: positive electrospray mode, capillary voltage 3500 V, drying 
gas (N2) 12 L/min at 350 °C, nebuliser gas (N2) pressure 50 psi, SIM m/z 192, 
fragmentor voltage 50 V and 150 V. Samples for LC-MS analysis were 
dissolved in acetonitrile/water (1:1, containing 0.1% formic acid) at a 
concentration of 10 µg/mL. The injection volume was 0.5 µL, flow rate was 0.2 
mL/min and the column temperature was 30 °C. Total run time was 25 min. 
 
2.3.3 High-resolution mass spectrometry 
 
Atmospheric pressure chemical ionization (APCI) experiments were carried 
out on a Bruker micrOTOF-Q III mass spectrometer interfaced to a Dionex 
UltiMate 3000 LC. The Agilent tuning mix APCI-TOF was used for mass 
calibration. Masses were recorded over a range of m/z 100–1600. Operating 
conditions were as follows: capillary voltage 4000 V, corona 4000 nA, 
nebulizer gas 2.0 bar, drying gas flow rate 3.0 L/min, drying gas temperature 
100–200 °C, vaporizer temperature 100–400 °C. MicroTof control and HyStar 
software were used for data analysis. 
 
2.3.4 Nuclear magnetic resonance spectroscopy 
 
All analytes were prepared in deuterated dimethyl sulfoxide (DMSO-d6) at a 
concentration of 20 mg/mL. 1H (600 MHz) and 13C (150 MHz) spectra were 
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recorded on a Bruker AV600 NMR spectrometer using a 5 mm TCI cryoprobe. 
1H NMR spectra were referenced to an external TMS reference at δ = 0 ppm. 
 
2.3.5 Gas chromatography solid-state infrared analysis 
 
Samples were analyzed using a GC-solid phase-IR-system that consisted of 
an Agilent GC 7890B (Waldbronn, Germany) with probe sampler Agilent 
G4567A and a DiscovIR-GC™ (Spectra Analysis, Marlborough, MA, USA). 
The column eluent was cryogenically accumulated on a spirally rotating ZnSe 
disk cooled by liquid nitrogen. IR spectra were recorded through the IR-
transparent ZnSe disk using a nitrogen-cooled MCT detector. GC parameters: 
injection in splitless mode with an injection port temperature set at 240 °C and 
a DB-1 fused silica capillary column (30 m × 0.32 mm i.d., 0.25 µm film 
thickness). The carrier gas was helium with a flow rate of 2.5 mL/min and the 
oven temperature program was as follows: 80 °C for 2 min, ramped to 290 °C 
at 20 °C/min, and held at for 20 min. The transfer line was heated at 280°C. 
Infrared conditions: oven temperature, restrictor temperature, disc 
temperature, and Dewar cap temperatures were 280 °C, 280 °C, -40 °C, and 
35 °C, respectively. The vacuum was 0.2 mTorr, disc speed 3 mm/s, spiral 
separation was 1 mm, wavelength resolution 4 cm-1 and IR range 650–4000 
cm-1. Acquisition time was 0.6 s/file with 64 scans/spectrum. Data were 
processed using GRAMS/AI Ver. 9.1 (Grams Spectroscopy Software Suite, 
Thermo Fischer Scientific, Dreieich, Germany) followed by implementation of 
the OMNIC Software, Ver. 7.4.127 (Thermo Electron Corporation, Dreieich, 
Germany). 
 
2.3.6 Infrared spectroscopy 
 
IR spectra were recorded on a Perkin Elmer Spectrum 100 FT-IR with 
Universal ATR sampling accessory (Perkin Elmer, Waltham, MA, USA). The 
wavelength resolution was set to 2 cm-1. IR spectra were collected in a range 
of 650–4000 cm-1 with 16 scans per spectrum. The IR data were processed 
using Spectrum Perkin Elmer Version 6.3.4 Software (Perkin Elmer, Waltham, 
MA, USA). 
 
2.3.7 X-ray crystallography  
 
Data for the 4-MPM vendor sample were collected on a Bruker APEX DUO 
using Cu Kα radiation (λ = 1.54184 Å). The sample was mounted on a 
Mitegen cryoloop and data collected at 100(2) K (Oxford Cobra cryosystem). 
Bruker APEX19 software was used to collect and reduce data, determine the 
space group. The data was solved with XT structure solution program20 and 
refined with the XL refinement package21 using Olex2.22 Absorption 
corrections were applied using SADABS 2014.23 All non-hydrogen atoms 
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were refined anisotropically. NH2 hydrogen atoms were located and freely 
refined. All other hydrogen atoms were assigned to calculated positions using 
a riding model with appropriately fixed isotropic thermal parameters. Crystal 
data and structure refinement parameters were as follows: 
Representative 4-MPM vendor sample: C12H18NOCl, M (g/mol) = 227.72, SG 
= P212121 (no. 19), a (Å) = 6.7094(3), b (Å) = 7.5835(4), c (Å) = 24.6346(11), 
V (Å3) = 1253.43(10), Z = 4, T (K) = 100, µ(CuKα) (mm-1) = 2.492, Reflections 
measured = 21970, Reflections unique = 2336, Rint = 0.0341, Rsigma = 0.0189, 
S = 1.041, R1* (I > 2σ(I)) = 0.0239, wR2† (all data) = 0.0613, Flack parameter 
= 0.388(15), * = R1 = Σ||Fo|-|Fc||/Σ|Fo|, † = wR2 = [Σ[w(Fo
2-Fc
2)/Σ[w(Fo
2)2]0.5 
 
 
2.4  Monoamine transporter assays 
 
Male Sprague-Dawley rats (250–300 g, Charles River Laboratories, 
Wilmington, MA, USA) were housed 2 per cage and maintained on a 12 h 
light-dark cycle. Food and water were provided ad libitum. Animal use 
procedures were conducted in accordance with the NIH Guide for the Care 
and Use of Laboratory Animals, and the Animal Care and Use Committee of 
the Intramural Research Program of the National Institute on Drug Abuse 
(Baltimore, MD, USA). Rats were euthanized by CO2 narcosis and brains 
were processed to yield synaptosomes as previously described.24-26 Briefly, 
rat caudate (for DAT assays) or whole brain minus cerebellum and caudate 
(for NET and SERT assays) was homogenized in ice-cold 10% sucrose. After 
12 strokes with a Potter-Elvehjem homogenizer, the homogenates were 
centrifuged at 1,000 g for 10 min at 4°C and the supernatants (i.e., 
synaptosomal preparations) were retained on ice.  
 
For uptake assays, synaptosomes were incubated with different 
concentrations of the test drugs in the presence of 5 nM [3H]dopamine, 10 nM 
[3H]norepinephrine or 5 nM [3H]5-HT for DAT, NET or SERT assays, 
respectively. To optimize uptake for a single transporter, unlabeled blockers 
were included that prevented uptake of [3H]transmitters by competing 
transporters (Supporting Information). The uptake assays were terminated by 
vacuum filtration and retained radioactivity was quantified by scintillation 
counting. For release assays, 9 nM [3H]-1-methyl-4-phenylpyridinium 
([3H]MPP+) was used as the radiolabelled substrate for DAT and NET, 
whereas 5 nM [3H]5-HT was used as the radiolabelled substrate for SERT. All 
buffers used in the release assay methods contained 1 µM reserpine to block 
vesicular uptake of substrates. The selectivity of release assays was 
optimized for a single transporter by including unlabeled blockers to prevent 
the uptake of [3H]MPP+ or [3H]5-HT by competing transporters (Supporting 
information), and the non-selective monoamine oxidase inhibitor pargyline (50 
µM) was added to prevent enzymatic degradation of monoamines. 
Accepted for publication in Drug Testing and Analysis 13.04.2018 
	 11 
Synaptosomes were preloaded with radiolabelled substrates in Krebs-
phosphate buffer for 1 h (steady state). Release assays were initiated by 
adding 850 µL of preloaded synaptosomes to 150 µL of test drug. The release 
assays were terminated by vacuum filtration and retained radioactivity was 
quantified by scintillation counting.  
 
Effects of test drugs on uptake or release were expressed as % of control 
uptake or % of maximum release, respectively. Maximum release (Emax) was 
defined as the release produced by tyramine at doses that evoke the efflux of 
all ‘releasable’ tritium by synaptosomes (10 µM tyramine for DAT and NET 
assay conditions, and 100 µM tyramine for SERT assay conditions). Effects of 
test drugs on uptake inhibition and release were analyzed by nonlinear 
regression using GraphPad Prism 7 (GraphPad Scientific, San Diego, CA). 
Dose-response values for uptake inhibition and release were fit to the 
equation Y(x) = Ymin + (Ymax - Ymin) / (1 + 10exp[(logP50 - logx)] x n), where x is 
the concentration of the compound tested, Y(x) is the response measured, 
Ymax is the maximal response, P50 is either IC50 (the concentration that yields 
half-maximal uptake inhibition) or EC50 (the concentration that yields half-
maximal release), and n is the Hill Slope parameter. 
 
3. Results and discussion 
 
Three samples, two advertised as 4-MPM and one as 3-MPM, were obtained 
from two different Internet retailers and subjected to extensive 
characterization using a variety of analytical platforms. One of the vendor 
samples of 4-MPM consisted of crystals whereas the other was a powder. 
The 3-MPM vendor sample was in powder form. The identity of the vendor 
samples was found to be consistent with the information given on the product 
labels. In addition, the identity of each vendor sample was verified by targeted 
organic synthesis of each of the methylphenmetrazine positional isomers 
including the 2-MPM isomer. The presence of positional isomers remains a 
challenge for forensic scientists tasked with the unique identification of a 
specific NPS. In an attempt to overcome this challenge, it remains important 
to provide analytical data on all possible positional isomers so that the correct 
isomer can be identified and reported.  Analytical details of both 3-MPM and 
4-MPM have been reported by the European project Response.27,28 However, 
extensive analytical data on 4-MPM and its positional isomers appears to be 
lacking in the scientific literature.  
 
The synthesis schemes employed for the preparation of 3-MPM and 4-MPM 
were adapted from McLaughlin et al. (Figure 1B). The synthesis involved the 
bromination of the methylphenmetrazine starting material, e.g. 4-
methylpropiophenone (a), yielding 2-bromo-1-(4-methylphenyl)propan-1-one 
(b). This species was reacted with ethanolamine and N,N-
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diisopropylethylamine to give the intermediates 2-((2-hydroxyethyl)amino)-1-
(4-methylphenyl-)propan-1-one and 3-methyl-2-(4-methylphenyl)morpholin-2-
ol (c). Reduction to the alcohol (d) was achieved by reaction with sodium 
borohydride followed by reaction with concentrated sulfuric acid to aid 
cyclization and formation of the morpholine ring (e). This synthesis protocol 
was also followed for 2-MPM, however, sufficient yields for extensive 
characterization could not be achieved. Therefore, an alternative synthesis 
protocol utilizing N-methyl-2-pyrrolidone, instead of N,N-
diisopropylethylamine, was developed which afforded the required 2-MPM 
product.29 Similar to synthesis of the fluorophenmetrazine positional isomers 
previously reported, it was found most practical to generate the fumarate salts 
to induce crystallization.11 Each methylphenmetrazine isomer contains two 
chiral centers, which yield the potential for four stereoisomers and two 
racemic mixtures (i.e., cis- and trans-racemates) (Figure 1C). As expected, 
the preparation of the methylphenmetrazine isomers were consistent with the 
prior synthesis of phenmetrazine where the formation of the more stable 
trans-isomer was reported.11,30,31 X-ray crystallography analysis of the 4-MPM 
vendor sample confirmed that the sample was consistent with the trans-form 
and that it was the hydrochloride salt. In addition, the chromatographic and 
NMR spectroscopy investigations confirmed that the vendor products were of 
high purity.  
 
3.1. Analytical features 
 
3.1.1 Gas chromatography mass spectrometry 
 
Initial analysis of the underivatized isomers by GC-MS failed to result in 
separation between the 2- and 3-MPM isomers, however, separation from the 
4-MPM isomer was achieved (Figure 2A). The electron ionization (EI) mass 
spectral data recorded for each isomer were identical (Figure 2C). A proposed 
fragmentation pathway for the underivatized methylphenmetrazine isomers 
under EI-MS conditions is shown in Figure 3A and, as expected, follows the 
same mass spectral pattern previously reported for fluorophenmetrazine 
positional isomers.11 In the EI-MS of each underivatized isomer, the molecular 
ion was detected at m/z 191. The loss of a diethylamine entity from the 
molecular ion leads to the formation of an oxonium ion at m/z 119 (C8H7O
+). A 
further loss of CO from the oxonium species leads to the formation of the 
tropylium ion at m/z 91. Furthermore, the fragment observed at m/z 71 may 
be represented by the loss of 3-methylbenzaldehyde from the parent structure 
leading to the formation of a radical cation ion represented by C4H9
+. A loss 
of a methyl group from this entity is thought to lead to the formation of a 2,3-
dihydroazet-1-ium (C3H6N
+) species at m/z 56. The fragment observed at m/z 
42 may reflect the loss of an oxetane species from the parent molecule that 
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caused the formation of 2H-azirin-1-ium species (C2H4N
+) at m/z 42. 
 
In an attempt to improve chromatographic separation, derivatization of the 
samples with trifluoroacetic anhydride (TFAA) was employed and dramatically 
improved the separation between all three isomers, with retention times of 
15.85, 16.05 and 16.34 min recorded for 3-, 2- and 4-MPM isomers, 
respectively (Figure 2B). The EI-MS data for the methylphenmetrazine-TFAA 
isomers were identical (Figure 2D) and some of the fragments were 
consistent with those reported in previous studies on 
amphetamine/phenmetrazine-based compounds that have been derivatized 
with TFAA.11,32 The proposed fragmentation pattern for the 
methylphenmetrazine-TFAA isomers is outlined in Figure 3B. In the EI mass 
spectra of each methylphenmetrazine-TFAA isomer, the molecular ion was 
detected at m/z 287. The fragment observed at m/z 218 might have been the 
result of radical loss of CF3 via cleavage of the nitrogen in the morpholine 
ring. A further loss of carbon monoxide would be consistent with m/z 190.  
Two dominant fragments were observed at m/z 167 and m/z 70. The m/z 167 
indicated a potential loss of the oxonium species, which is suggested to give 
rise to a TFAA-azetidine species (C6H8F3NO
+). The base peak at m/z 70 may 
be accounted for by the loss of the ring substituted methylbenzyl alcohol, 
which is proposed to form an azete species (2-methyl-2,3-dihydroazete, 
C4H8N
+). In addition, the loss of a TFAA-diethylamine entity from the 
molecular ion leads to the formation of an oxonium ion at m/z 119 (C8H7O
+). 
The fragment at m/z 54 may reflect the formation of an aziridine species 
(C3H6N
+). The GC-EI-MS data recorded for the vendor samples of 3- and 4-
MPM (underivatized/derivatized) were consistent with the data of the 
respective synthesized reference standard (Supporting Information). 
 
3.1.2 Liquid chromatography mass spectrometry 
 
Satisfactory separation of all three methylphenmetrazine isomers was 
achieved with retention times of 13.06 min, 16.70 min and 17.33 min for 2-
MPM, 3-MPM and 4-MPM, respectively (Figure 4A). The 2-MPM isomer was 
completely separated from the other two positional isomers, however, only 
partial separation was achieved for the 3- and 4-MPM isomers. Electrospray 
ionization (ESI) single quadrupole mass spectra were obtained from in-source 
collision induced dissociation (CID) at increased fragmentor voltage (150 V) 
(Figure 4B) and the suggested dissociation pathways are shown in Figure 4C. 
The fragmentation pattern of the MPM isomers were consistent with the 
fragmentation pattern also recorded for the FPM isomers.11 The protonated 
molecule [M+H]+ was present in all spectra at m/z 192. The formation of m/z 
174 might have represented a loss of methanol from the protonated molecule, 
presumably consistent with C12H16N
+. The m/z 148 ion might have reflected a 
loss of ethylene oxide from the protonated molecule to form an aziridine 
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species. The product ion at m/z 131 may be represented by the formation a 
stabilized allylic cation and might have formed following the loss of 
ethenamine (C2H5N) from m/z 174 and/or the loss of NH3 from the aziridine 
species at m/z 148.  The fragments at m/z 105 and 91 may be represented by 
the formation of a methylium and tropylium species, respectively. The LC-ESI-
MS data recorded for the vendor samples of 3- and 4-MPM were consistent 
with the data recorded for the respective synthesized reference standard 
(Supporting Information). 
 
3.1.3 X-ray crystal analysis 
 
4-MPM (vendor sample) crystallizes in the orthorhombic space group P212121. 
Crystallographic and refinement data are listed in the experimental section 
and a full numbering scheme figure is shown in the Supporting Information 
section. The two chiral centres C5 and C6 are shown as R (Figure 5), 
although the Flack parameter indicates that the model is not enantiopure. The 
solid state structure of 4-MPM is very similar to that of the parent 
phenmetrazine hydrochloride (PMHCl).33 An overlay of the morpholine ring 
shows only minor differences in hydrogen atom placement with a difference in 
the twist of the phenyl to morpholine rings (plane twist in: 1, 72°; PMHCl ca. 
77° and ca. 94° in phendimetrazine bitartrate34 (Supporting Information). In 
solution, the structure has also been elucidated by NMR, which indicates that 
H5 and H6 are also trans to each other (J = 9.9 Hz, full assignment given in 
Supporting Information) also giving the threo conformation seen in the solid 
state. In 4-MPM, as in PMHCl, there are significant intermolecular N…Cl 
hydrogen bonds with d(N…Cl) = 3.1243(16) and 3.0768(16)i Å with angles of 
159(2) and 173(2) ° respectively (symmetry codes used to generate 
equivalent atoms: (i) x+1/2,-y+3/2,-z+2). The crystal packing in 4-MPM is 
quite different to that in PMHCl. The 4-MPM molecules interdigitate and pack 
head to tail in layers ca. 15 Å wide parallel to the c-axis, with the Cl atoms in a 
staggered arrangement (Supporting Information). There are further weaker 
C…Cl (3.6-3.74 Å) and C…O (C10…O4 3.512(2) Å) intermolecular 
interactions which are also seen in an analysis of the Hirshfeld surface 
(Supporting Information). 
 
3.2 Pharmacology 
 
As a first step in characterizing the monoamine transporter activity of the 
compounds, we tested the effects of phenmetrazine, 2-MPM, 3-MPM and 4-
MPM in uptake inhibition assays. The dose-response curves are depicted in 
Figure 6 and corresponding IC50 values are given in Table 1.  Phenmetrazine, 
2-MPM and 4-MPM were efficacious uptake blockers at DAT, NET and SERT 
with IC50 values in the low µM range, whereas 3-MPM was substantially 
weaker at DAT and SERT (Table 1). 4-MPM was about 3.5-fold more potent 
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than 2-MPM at DAT, with IC50 values of 1.93 and 6.74 µM, respectively. In 
addition, 4-MPM was nearly 10-fold more potent than 2-MPM and 
phenmetrazine at SERT. All compounds were fully efficacious uptake blockers 
at NET with potencies ranging from 1.2 to 5.2 µM for phenmetrazine and 3-
MPM. The results from the uptake inhibition experiments demonstrated that 
phenmetrazine analogs interact with monoamine transporters, but uptake 
assays cannot differentiate between ligands acting as non-transportable 
uptake blockers versus those acting as transportable substrates. Thus, we 
next tested the compounds in transporter release assays which can detect the 
activity of substrate-type releasing agents. 
 
Figure 7 shows the effects of 2-MPM, 3-MPM and 4-MPM on release of 
[3H]MPP+ via DAT and NET, and [3H]serotonin via SERT. The corresponding 
EC50 values are presented in Table 2.  Consistent with prior findings, we 
found that phenmetrazine is a potent releaser at DAT and NET, with negligible 
activity at SERT. The data obtained for the 2-, 3- and 4-MPM isomers 
exhibited sigmoidal dose-response curves indicative of fully efficacious 
release activity across all three transporters (Figure 7; Table 2). Importantly, 
the addition of a methyl moiety to the phenmetrazine molecular structure 
increased the relative potency at SERT. Moving the methyl group from the 
ortho- or meta- position to the para- position leads to a substantial increase in 
the selectively for SERT, so much so that 4-MPM is essentially a non-
selective monoamine releaser, with similar potency at DAT (227 nM), NET (62 
nM) and SERT (86 nM). In this regard, the release data are generally 
consistent with the uptake inhibition data, which show greater relative potency 
toward SERT for 4-MPM when compared to 2- and 3-MPM. The non-selective 
profile of monoamine release produced by 4-MPM is similar to the club drug 
3,4-methylenedioxymethamphetamine (MDMA) and the synthetic cathinone 
3,4-methylenedioxymethcathinone (methylone).24 The unique psychoactive 
properties of MDMA reside in its more potent substrate activity at SERT when 
compared to more classic stimulants like amphetamine and cathinone 35, 
which display potent substrate activity at DAT and NET but not at SERT. 
Previous studies on the pharmacological activity of 2-, 3- and 4-
fluorophenmetrazine (FPM) found that addition of the fluorine atom to the 
phenyl ring increased activity at SERT, but none of the FPM isomers were 
able to affect SERT releasing activity to the same extent as 4-MPM.13 Overall, 
these findings are in agreement with previous studies, which demonstrate 
increased steric bulk of the phenyl ring substituent increases activity at SERT 
relative to DAT for amphetamine type compounds.36,3735,36  
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4. Conclusion 
 
The availability of NPS on the recreational drug market continues to create 
challenges for scientists in the forensic, clinical and toxicology fields. This 
report provides comprehensive analytical and pharmacological data on ortho-, 
meta- and para-substituted methylphenmetrazine isomers. The combination 
of test purchases, analytical characterization, targeted organic synthesis and 
pharmacological evaluation of NPS and their isomers is an effective approach 
for the provision of data on these substances as they emerge in the 
marketplace. The analytical characterization of three vendor samples 
revealed the presence of 4-MPM in two of the samples and 3-MPM in the third 
sample, which agreed with the product labels. The pharmacological findings 
suggest that 2-MPM and 3-MPM will exhibit stimulant properties similar to the 
parent compound phenmetrazine, whereas 4-MPM may display entactogen 
properties more similar to MDMA.  
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Table 1.  IC50 potency values for phenmetrazine and its methyl ring-
substituted analogs to inhibit [3H]neurotransmitter uptake at DAT, NET and 
SERT in rat brain synaptosomes 
Drug [3H]Dopamine 
uptake at 
DAT 
IC50 (nM) 
[3H]Norepinephrine 
uptake at NET 
IC50 (nM)  
[3H]5-HT  
uptake at 
SERT 
IC50 (nM)  
DAT/SERT 
ratio 
Phenmetrazine  933 ± 57   
 
1163 ± 197   
 
3575 ± 
836 
3.8 
2-MPM 6586 ± 1311  
 
2595 ± 633  
 
4011 ± 
317   
 
0.6 
3-MPM >10,000   
 
5210 ± 1650  
 
>10,000   
 
n.d. 
4-MPM 1926 ± 207   
 
1933 ± 392   
 
408 ± 17   
 
0.2 
Data are mean ± SD for N=3 experiments performed in triplicate.   
DAT/SERT ratio = (DAT IC50 
-1)/(SERT IC50 
-1); higher value indicates greater DAT 
selectivity. 
	
 
Table 2.  EC50 potency values for phenmetrazine and its methyl ring-
substituted analogs to release [3H]MPP+ at DAT or NET, or [3H]5-HT at SERT 
in rat brain synaptosomes 
Drug Release at 
DAT 
EC50 (nM)  
[% Emax] 
Release at 
NET 
EC50 (nM)  
[% Emax] 
Release at 
SERT 
EC50 (nM)  
[% Emax] 
DAT/SERT 
ratio 
Phenmetrazine  70 ± 9   
[101] 
 
29 ± 4   
[95] 
>10,000 >142.0 
2-MPM 374 ± 38   
[104] 
 
102 ± 12   
[91] 
1758 ± 336   
[101] 
4.7 
3-MPM 1321 ± 218   
[110] 
 
509 ± 73   
[90] 
5383 ± 947   
[111] 
4.1 
4-MPM 227 ± 30   
[99] 
 
62 ± 9   
[90] 
86 ± 12   
[88] 
0.4 
Data are mean ± SD for N=3 experiments performed in triplicate.   
% Emax is defined as % of maximal releasing response induced by 10 µM tyramine 
for DAT and NET or 100 µM tyramine for SERT. 
DAT/SERT ratio = (DAT EC50 
-1)/(SERT EC50 
-1); higher value indicates greater DAT 
selectivity. 
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Figure 1. A. Chemical structures of phenmetrazine, its N-methyl derivative 
phendimetrazine and the methylphenmetrazine (MPM) positional isomers. B. The 
synthesis pathway employed for the preparation of 2-, 3- and 4-MPM isomers. C. 
Structural representation of all four MPM enantiomers. 
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Figure 2. Gas chromatographic (GC) separation achieved for the underivatized MPM 
isomers (A) and the TFAA-MPM derivatives (B). The electron ionization (EI) mass 
spectra recorded for underivatized 4-MPM and the TFAA-MPM derivatives are 
shown in Figure 2C and 2D, respectively. 
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Figure 3. A. A proposed fragmentation pathway for underivatized MPM under EI-MS 
conditions. B. A proposed fragmentation pattern for the MPM-TFAA isomers under 
EI-MS conditions. 
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Figure 4. A. HPLC separation achieved for all three methylphenmetrazine isomers. 
B. The product ion spectra obtained from in-source collision-induced dissociation 
(CID) at increased fragmentor voltage (150 V). C. A suggested dissociation pathway 
for the 4-MPM isomer. 
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Figure 5. Molecular structure achieved for 4-MPM vendor sample using x-ray crystal 
structure analysis. 
 
 
 
Figure 6. Dose-response effects of phenmetrazine (PM), 2-MPM, 3-MPM and 4-
MPM on inhibition of [3H]neurotransmitter uptake at DAT, NET and SERT in rat brain 
synaptosomes. For uptake assays, 5 nM [3H]dopamine, 10 nM [3H]norepinephrine or 
5 nM [3H]5-HT were incubated with different concentrations of test drugs under assay 
conditions optimized for DAT, NET or SERT, respectively. Data are expressed as % 
of control uptake (mean ± SD) for n = 3 experiments performed in triplicate. 
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Figure 7. Dose-response effects of phenmetrazine (PM), 2-MPM, 3-MPM and 4-
MPM on release of [3H]substrates by DAT, NET and SERT in rat brain 
synaptosomes. For release assays, synaptosomes were preloaded with 9 nM 
[3H]MPP+ for DAT and NET or 5 nM [3H]5-HT for SERT, then incubated with different 
concentrations of test drugs to evoke release via reverse transport. Data are 
expressed as % of maximal release (mean ± SD) for n = 3 experiments performed in 
triplicate. 
 
 
 
